Ascentage Pharma Group International (NASDAQ:AAPG) Sees Unusually-High Trading Volume – Here’s Why

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw strong trading volume on Thursday. Approximately 11,255 shares traded hands during trading, an increase of 65% from the previous session’s volume of 6,819 shares. The stock last traded at $15.1290 and had previously closed at $16.34.

Wall Street Analyst Weigh In

AAPG has been the subject of several research reports. Citigroup assumed coverage on shares of Ascentage Pharma Group International in a report on Wednesday, October 14th. They issued a “buy” rating and a $46.00 price target for the company. BTIG Research restated a “buy” rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Friday, August 21st. Citizens Jmp started coverage on Ascentage Pharma Group International in a research note on Tuesday, October 13th. They set a “market outperform” rating and a $35.00 target price on the stock. William Blair initiated coverage on shares of Ascentage Pharma Group International in a research report on Friday, October 16th. They issued an “outperform” rating for the company. Finally, JPMorgan Chase & Co. dropped their target price on Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating on the stock in a report on Thursday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating and twelve have issued a Buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $43.90.

Ascentage Pharma Group International Price Performance

The company’s 50-day moving average is $16.15 and its 200 day moving average is $18.73. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.22 and a quick ratio of 1.18.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The company had revenue of $22.24 million during the quarter. On average, research analysts expect that Ascentage Pharma Group International – Unsponsored ADR will post -2.43 earnings per share for the current year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.